

ModernGraham Valuation

Company Name:

Regeneron
Pharmaceuticals Inc

Company Ticker

REGN

Date of Analysis

8/4/2016



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

1. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$46,218,576,706	Pass
2. Sufficiently Strong Financial Condition	Current Ratio > 2	3.41	Pass
3. Earnings Stability	Positive EPS for 10 years prior		Fail
4. Dividend Record	Dividend Payments for 10 years prior		Fail
5. Earnings Growth	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	-580.81%	Fail
6. Moderate PEmg Ratio	PEmg < 20	76.12	Fail
7. Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	13.15	Fail

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	3.41	Pass
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	0.00	Pass
3. Earnings Stability	Positive EPS for 5 years prior		Pass
4. Dividend Record	Currently Pays Dividend		Fail
5. Earnings Growth	EPSmg greater than 5 years ago		Pass

Suitability

Defensive	No
Enterprising	Yes

Stage 2: Determination of Intrinsic Value

EPSmg	\$5.69
MG Growth Estimate	15.00%
MG Value	\$219.22
MG Value based on 3% Growth	\$82.56
MG Value based on 0% Growth	\$48.40
Market Implied Growth Rate	33.81%

MG Opinion

Current Price	\$433.40
% of Intrinsic Value	197.70%
Opinion	Overvalued
MG Grade	C-

Stage 3: Information for Further Research

Net Current Asset Value (NCAV)	\$8.70
Graham Number	\$80.54
PEmg	76.12
Current Ratio	3.41
PB Ratio	13.15
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend Growth	0

Useful Links: [ModernGraham tagged articles](#) [Morningstar](#)
[Google Finance](#) [MSN Money](#)
[Yahoo Finance](#) [Seeking Alpha](#)
[GuruFocus](#) [SEC Filings](#)

EPS History		EPSmg History	
Next Fiscal Year Estimate	\$8.04	Next Fiscal Year Estimate	\$5.69
Dec2015	\$5.52	Dec2015	\$4.12
Dec2014	\$2.98	Dec2014	\$2.92
Dec2013	\$3.72	Dec2013	\$2.33
Dec2012	\$6.75	Dec2012	\$1.16
Dec2011	-\$2.45	Dec2011	-\$1.56
Dec2010	-\$1.26	Dec2010	-\$1.18
Dec2009	-\$0.85	Dec2009	-\$1.22
Dec2008	-\$1.00	Dec2008	-\$1.29
Dec2007	-\$1.59	Dec2007	-\$1.39
Dec2006	-\$1.77	Dec2006	-\$1.37
Dec2005	-\$1.71	Dec2005	-\$1.30
Dec2004	\$0.74	Dec2004	-\$1.17
Dec2003	-\$2.13	Dec2003	-\$1.96
Dec2002	-\$2.83	Dec2002	-\$1.68
Dec2001	-\$1.81	Dec2001	-\$0.99
Dec2000	-\$0.66	Dec2000	-\$0.61
Dec1999	-\$0.74	Balance Sheet Information 3/1/2016	
Dec1998	-\$0.28	Total Current Assets	\$3,133,379,000
Dec1997	-\$0.40	Total Current Liabilities	\$919,724,000
Dec1996	-\$1.32	Long-Term Debt	\$0
		Total Assets	\$5,904,460,000
		Intangible Assets	\$0
		Total Liabilities	\$2,139,378,000
		Shares Outstanding (Diluted Average)	114,228,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other
ModernGraham
posts about the
company

[Regeneron Pharmaceuticals Inc. Annual Valuation – 2015 \\$REGN](#)
[16 Companies in the Spotlight this Week – 4/19/14](#)
[Regeneron Pharmaceuticals Inc. \(REGN\) Annual Valuation – 2014](#)

Other
ModernGraham
posts about related
companies

[AmersourceBergen Corp Valuation – July 2016 \\$ABC](#)
[Perrigo Co PLC Valuation – July 2016 \\$PRGO](#)
[AbbVie Inc Valuation – July 2016 \\$ABBV](#)
[Gilead Sciences Inc Valuation – July 2016 \\$GILD](#)
[Eli Lilly and Company Valuation – July 2016 \\$LLY](#)
[Zoetis Inc Valuation – June 2016 \\$ZTS](#)
[Merck & Co Inc Valuation – March 2016 \\$MRK](#)
[Bristol-Myers Squibb Company Valuation – February 2016 \\$BMY](#)
[Amgen Inc Valuation – February 2016 \\$AMGN](#)
[Merck & Co Inc Valuation – March 2016 \\$MRK](#)